bpc-157 human studies risks Are there concerns with the peptide BPC-157? Here's a summary of 36 research examining its effects on healing. Comment "podcast" and I'll send you a link to the full episode: The Regeneration or Risk? A Narrative

Sikiric P, Kokot A, Kralj T, Zlatar M, Masnec S, Lazic R, Loncaric K, Oroz K, Sablic M, Boljesic M, Antunovic M, Sikiric S, Strbe S, Stambolija V, Beketic Oreskovic L, Kavelj I, Novosel L, Zubcic S, Krezic I, Skrtic A, Jurjevic I, Boban Blagaic A, Seiwerth S, Staresinic M

Finally, BPC 157 improves sciatic nerve healing [41] when applied intraperitoneally, intragastrically, or locally at the site of anastomosis shortly after injury or directly into the tube after non-anastomosed nerve tubing (7-mm nerve segment resection)

Direct delivery into circulation allows the peptide to reach target tissues without the absorption loss associated with oral forms

Because AOD 9604 has not completed the full clinical development pathway, its comprehensive side-effect profile in humans is not well characterised and should not be assumed to be benign